Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 7/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20964599 | 0.92 | LMNA (0.59) | LMNAHTTMEN1MAPK1KMT2A | |
| SCHEMBL20964553 | 0.91 | ALDH1A1 (0.69) | LMNAHTTMEN1MAPK1KMT2A | |
| SCHEMBL20965377 | 0.91 | LMNA (0.58) | LMNAHTTMEN1MAPK1KMT2A | |
| SCHEMBL20964705 | 0.85 | ALDH1A1 (0.49) | LMNAHTTMEN1MAPK1KMT2A | |
| SCHEMBL20964680 | 0.84 | LMNA (0.82) | LMNAHTTMEN1MAPK1KMT2A | |
| SCHEMBL20964683 | 0.84 | LMNA (0.53) | LMNAHTTMAPK1KMT2ATSHR | |
| SCHEMBL20964637 | 0.84 | LMNA (0.60) | LMNAMEN1MAPK1KMT2ATSHR | |
| SCHEMBL20964636 | 0.83 | SMN1; SMN2 (0.53) | LMNAHTTMEN1KMT2ATSHR | |
| SCHEMBL20965289 | 0.83 | ALDH1A1 (0.67) | LMNAHTTMEN1KMT2ATSHR | |
| SCHEMBL20964548 | 0.82 | ALDH1A1 (0.59) | LMNAMEN1KMT2ATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851096-B2 | Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190127361-A1 | Therapeutic Compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127361-A1 | Therapeutic Compounds | SDHA, SLC10A1, SERPINC1 | LMNA 1413/4885HTT 2154/4885MEN1 179/4885 |
| US-10851096-B2 | Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents | SERPINC1, F12, RPL35 | LMNA 897/4885HTT 2335/4885MEN1 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.